Solid Dispersion Compositions for Pediatric Cystic Fibrosis Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for treating cystic fibrosis, particularly in pediatric patients, face challenges with dosing inaccuracies and administration difficulties due to the use of crushed tablets and powders, leading to absorption issues and therapeutic failures.
Innovation Solution
Development of stable, bioavailable pharmaceutical compositions in the form of solid dispersions, including mini-tablets and granules, formulated with excipients such as fillers, sweeteners, and lubricants, which can be easily administered with food or liquids, ensuring accurate dosing and improved bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If crushed tablets or powders are used for administration, then flexibility in administration is improved, but dosing accuracy deteriorates
Solution Approach 1:
The invention divides the pharmaceutical composition into discrete, pre-measured mini-tablets or granules. Each unit contains a precise amount of active ingredient, allowing flexible administration (multiple units can be given together or separately) while maintaining dosing accuracy. This segmentation resolves the contradiction by providing both adaptability in how the dose is administered and precision in the actual dosage delivered.
Solution Approach 2:
The invention changes the physical form parameter from crushed tablets/powders to solid dispersions in the form of mini-tablets or granules. This parameter change enables accurate dosing through controlled manufacturing of discrete units while maintaining administration flexibility. The solid dispersion form specifically addresses bioavailability issues while the discrete unit structure solves the dosing accuracy problem.
2Stability of the object's composition
If traditional tablet forms are used, then manufacturing stability is improved, but bioavailability and absorption deteriorate
Solution Approach 1:
The invention changes the physical state parameter of the active ingredient from crystalline to amorphous within a solid dispersion matrix. This parameter change dramatically improves bioavailability and absorption while the solid dispersion formulation maintains compositional stability. The amorphous state increases solubility and dissolution rate, directly addressing the bioavailability problem while the controlled solid dispersion structure preserves formulation stability.
Solution Approach 2:
The invention creates a composite material system consisting of the active ingredient embedded in a solid dispersion matrix with excipients. This composite structure provides both the stability needed for manufacturing and storage while enabling enhanced bioavailability through the amorphous dispersed phase. The composite material approach resolves the contradiction by combining stabilizing excipients with the bioavailability-enhancing amorphous structure.
3Reliability
If solid dispersions are formulated, then bioavailability is improved, but manufacturing complexity increases
Solution Approach 1:
The invention focuses on optimizing key parameters of the solid dispersion formulation (amorphous content, excipient ratios, particle size) to achieve reliable bioavailability enhancement. By controlling these critical parameters during manufacturing, the process becomes more predictable and manageable despite the inherent complexity of solid dispersion technology. This parameter control approach reduces manufacturing complexity while maintaining the bioavailability benefits.
Data Source
AI summary
The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.